Canagliflozin and Myocardial Micro-perfusion
Conditions: Type 2 Diabetes; Cardiovascular Diseases; Cardiac Perfusion Defect Intervention: Drug: Canagliflozin 100mg or Sitagliptin 100mg Sponsor: Shanghai Zhongshan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Canagliflozin | Cardiology | Diabetes | Endocrinology | Heart | Hospitals | Invokana | Perfusion | Research